ArticleInfection and immunity1996
Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.
Article in Infection and immunity, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Estrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system.Cell reports · 2022Article
- Review
- Article
- Review
- Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.Infection and immunity · 2010Article
- Canadian clinical practice guidelines for invasive candidiasis in adults.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2010Article
- Complement C3 plays an essential role in the control of opportunistic fungal infections.Infection and immunity · 2009Article
- Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.Molecular immunology · 2009Article
- Candidiasis--do we need to fight or to tolerate the Candida fungus?Folia microbiologica · 2007Review
- Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.Infection and immunity · 2006Article
- Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.Infection and immunity · 2006Article
- The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein.Infection and immunity · 2004Article
- Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.Infection and immunity · 2004Article
- Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast.Infection and immunity · 2001Article
- Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.Infection and immunity · 1998Article
- Minimum chemical requirements for adhesin activity of the acid-stable part of Candida albicans cell wall phosphomannoprotein complex.Infection and immunity · 1998Article
- Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway.Infection and immunity · 1998Article
- Cell wall and secreted proteins of Candida albicans: identification, function, and expression.Microbiology and molecular biology reviews : MMBR · 1998Review
- A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity.Infection and immunity · 1997Article
- Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans.Infection and immunity · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Candida albicans is a potent activator of the complement system. The objective of this study was to characterize factors that influence the kinetics for activation of C3 and binding of C3 fragments to C. albicans. Factors that were examined included the surface properties of the yeast and contributions of the classical and alternative complement pathways. The results showed that incubation of hydrophobic, hydrophilic, or germinating yeast cells in normal human serum (NHS) containing radiolabeled C3 led to immediate accumulation of C3 on all three cell types, although the rate of accumulation of C3 on germinating cells was lower. An examination of the sites for early C3 binding showed that classical pathway initiation led to immediate, synchronous binding over the entire cell surface. A blockade of the classical pathway by absorption of putative classical pathway initiators or by chelation of calcium limited activation to the alternative pathway. Binding of C3 solely via the alternative pathway was characterized by a significant lag in the initial binding kinetics. In the absence of classical pathway initiation, the early cellular sites for C3 binding appeared as random, asynchronous foci of C3 that appeared to expand with time. The factor(s) mediating rapid deposition of C3 that was characteristic of the classical pathway initiation was reciprocally cross-absorbed by hydrophilic and hydrophobic C. albicans but was not removed by absorption of NHS with Saccharomyces cerevisiae, encapsulated Cryptococcus neoformans, or nonencapsulated C. neoformans. Delayed binding of C3 produced by absorption of serum was largely reversed by addition to the absorbed serum of immunoglobulin G isolated from NHS, indicating a significant role for a naturally occurring anti-C. albicans immunoglobulin C. in classical pathway initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.